SG11201408196RA - Designed ankyrin repeat proteins binding to platelet-derived growth factor - Google Patents
Designed ankyrin repeat proteins binding to platelet-derived growth factorInfo
- Publication number
- SG11201408196RA SG11201408196RA SG11201408196RA SG11201408196RA SG11201408196RA SG 11201408196R A SG11201408196R A SG 11201408196RA SG 11201408196R A SG11201408196R A SG 11201408196RA SG 11201408196R A SG11201408196R A SG 11201408196RA SG 11201408196R A SG11201408196R A SG 11201408196RA
- Authority
- SG
- Singapore
- Prior art keywords
- platelet
- growth factor
- derived growth
- ankyrin repeat
- repeat proteins
- Prior art date
Links
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 title 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 title 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12174020 | 2012-06-28 | ||
PCT/EP2013/063488 WO2014001442A1 (en) | 2012-06-28 | 2013-06-27 | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201408196RA true SG11201408196RA (en) | 2015-03-30 |
Family
ID=48699826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201408196RA SG11201408196RA (en) | 2012-06-28 | 2013-06-27 | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
Country Status (16)
Country | Link |
---|---|
US (2) | US9163070B2 (en) |
EP (1) | EP2867360B1 (en) |
JP (1) | JP2015522576A (en) |
KR (1) | KR20150023957A (en) |
CN (1) | CN104508129A (en) |
AU (1) | AU2013283296A1 (en) |
BR (1) | BR112014032316A2 (en) |
CA (1) | CA2877584A1 (en) |
HK (1) | HK1209156A1 (en) |
IL (1) | IL236428A0 (en) |
IN (1) | IN2014MN02522A (en) |
MX (1) | MX2014015825A (en) |
RU (1) | RU2014150224A (en) |
SG (1) | SG11201408196RA (en) |
WO (1) | WO2014001442A1 (en) |
ZA (1) | ZA201408872B (en) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI510246B (en) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | Modified binding proteins inhibiting the vegf-a receptor interaction |
KR20140032356A (en) | 2010-11-26 | 2014-03-14 | 몰리큘라 파트너스 아게 | Improved n-terminal capping modules for designed ankyrin repeat protein |
HUE046134T2 (en) | 2012-05-07 | 2020-02-28 | Allergan Inc | Method of treating amd in patients refractory to anti-vegf therapy |
EP2738180A1 (en) | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
CN105209483B (en) | 2013-05-31 | 2021-07-27 | 分子组合公司 | Designed ankyrin repeat proteins binding to hepatocyte growth factor |
WO2016005969A1 (en) | 2014-07-07 | 2016-01-14 | Yeda Research And Development Co. Ltd. | Method of computational protein design |
US20170226158A1 (en) * | 2014-08-11 | 2017-08-10 | Medimmune Limited | Intracellular antigen binding |
CN107148429B (en) | 2014-11-10 | 2021-12-03 | 豪夫迈·罗氏有限公司 | anti-PDGF-B antibodies and methods of use |
EP3218399A1 (en) | 2014-11-10 | 2017-09-20 | F. Hoffmann-La Roche AG | Bispecific antibodies and methods of use in ophthalmology |
KR20170082594A (en) | 2014-11-10 | 2017-07-14 | 에프. 호프만-라 로슈 아게 | Anti-ang2 antibodies and methods of use |
BR112017009817A2 (en) | 2014-11-10 | 2018-02-14 | Hoffmann La Roche | anti-il-1beta antibodies and methods of use |
EP4272838A3 (en) | 2015-04-02 | 2024-01-10 | Molecular Partners AG | Designed ankyrin repeat domains with binding specificity for serum albumin |
US10283384B2 (en) * | 2015-04-27 | 2019-05-07 | Taiwan Semiconductor Manufacturing Co., Ltd. | Method for etching etch layer and wafer etching apparatus |
WO2018054971A1 (en) | 2016-09-22 | 2018-03-29 | Molecular Partners Ag | Recombinant binding proteins and their use |
US10037890B2 (en) * | 2016-10-11 | 2018-07-31 | Lam Research Corporation | Method for selectively etching with reduced aspect ratio dependence |
US11127483B2 (en) | 2017-03-07 | 2021-09-21 | Igc Bio, Inc. | Computational pipeline for antibody modeling and design |
US11655293B2 (en) | 2018-02-22 | 2023-05-23 | Universitat Zurich | Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT |
EP3623382A1 (en) | 2018-09-14 | 2020-03-18 | Universität Zürich | Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct |
EP3768833A1 (en) | 2018-03-22 | 2021-01-27 | Charité - Universitätsmedizin Berlin | Crispr associated protein reactive t cell immunity |
WO2019238966A1 (en) | 2018-06-15 | 2019-12-19 | Universität Bern | LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES |
CA3113306A1 (en) | 2018-10-08 | 2020-04-16 | Universitat Zurich | Her2-binding tetrameric polypeptides |
WO2020104627A1 (en) | 2018-11-21 | 2020-05-28 | Universität Zürich | Photochemically induced conjugation of radiometals to small molecules, peptides and nanoparticles in a simultaneous one-pot reaction |
EP3677911A3 (en) | 2019-01-03 | 2020-07-29 | Universität Basel | Use of non-agonist ligands for suppression of metastasis |
EP3908274A1 (en) | 2019-01-11 | 2021-11-17 | Universitätsspital Basel | Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery |
WO2020207771A1 (en) | 2019-04-10 | 2020-10-15 | Universität Zürich | A method for determining the likelihood of a patient being responsive to cancer immunotherapy |
SG11202112921VA (en) | 2019-06-04 | 2021-12-30 | Molecular Partners Ag | Multispecific proteins |
WO2020245175A1 (en) * | 2019-06-04 | 2020-12-10 | Molecular Partners Ag | Recombinant 4-1bb binding proteins and their use |
MX2021014601A (en) | 2019-06-04 | 2022-02-11 | Molecular Partners Ag | RECOMBINANT PROTEINS OF BINDING TO FAP AND THEIR USE. |
US20220332845A1 (en) | 2019-09-05 | 2022-10-20 | Genome Biologics Ug | Inhibition of mthfd1l for use in hypertrophic heart disease and heart failure |
WO2021116469A2 (en) | 2019-12-11 | 2021-06-17 | Molecular Partners Ag | Recombinant peptide-mhc complex binding proteins and their generation and use |
WO2021122813A1 (en) | 2019-12-16 | 2021-06-24 | Universität Basel | Angiogenesis promoting agents for prevention of metastatic cancer |
WO2021176008A1 (en) | 2020-03-04 | 2021-09-10 | Cornell University | Agents targeting baf155 or brg1 for use in treatment of advanced prostate cancer |
US20230151118A1 (en) | 2020-04-06 | 2023-05-18 | Universität Zürich | Artc1 ligands for cancer treatment |
CA3176845A1 (en) | 2020-05-06 | 2021-11-11 | Patrick AMSTUTZ | Novel ankyrin repeat binding proteins and their uses |
US20240279290A1 (en) | 2020-05-14 | 2024-08-22 | Molecular Partners Ag | Multispecific proteins |
WO2021239844A1 (en) | 2020-05-27 | 2021-12-02 | Universitätsspital Basel | Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia in prediabetes |
WO2021239999A1 (en) | 2020-05-28 | 2021-12-02 | Universität Zürich | Il-12 pd-l1 ligand fusion protein |
KR20230048151A (en) | 2020-08-18 | 2023-04-10 | 유니버시타트 취리히 | CD25 biased anti-IL-2 antibody |
CA3202358A1 (en) | 2020-12-16 | 2022-06-23 | Andreas BOSSHART | Novel slow-release prodrugs |
WO2022171831A1 (en) | 2021-02-11 | 2022-08-18 | Universität Zürich | Use of markers found on lymph node metastatic samples for the prognosis of breast cancer |
US20240150475A1 (en) | 2021-03-09 | 2024-05-09 | Molecular Partners Ag | Novel darpin based cd123 engagers |
JP2024509904A (en) | 2021-03-09 | 2024-03-05 | モレキュラー パートナーズ アクチェンゲゼルシャフト | A novel DARPin-based multispecific T cell engager |
CA3211248A1 (en) | 2021-03-09 | 2022-09-15 | Nina RESCHKE | Novel darpin based cd33 engagers |
US20240156980A1 (en) | 2021-03-09 | 2024-05-16 | Molecular Partners Ag | Protease cleavable prodrugs |
WO2023012350A1 (en) | 2021-08-05 | 2023-02-09 | Immunos Therapeutics Ag | Combination medicaments comprising hla fusion proteins |
AU2022324711A1 (en) | 2021-08-05 | 2024-02-01 | Immunos Therapeutics Ag | A modified hla-b57 with increased expression levels |
WO2023021006A1 (en) | 2021-08-16 | 2023-02-23 | Universität Zürich | Il-1 targeting agents for treatment of pitiyriasis rubra pilaris |
WO2023036849A1 (en) | 2021-09-07 | 2023-03-16 | ETH Zürich | Identifying and predicting future coronavirus variants |
EP4163380A1 (en) | 2021-10-08 | 2023-04-12 | ETH Zurich | Device and method for manipulation of extracellular vesicles |
CN118354784A (en) | 2021-12-14 | 2024-07-16 | 分子合作伙伴股份公司 | Designed repeat domains with dual binding specificity and uses thereof |
WO2023110942A1 (en) | 2021-12-14 | 2023-06-22 | Charité-Universitätsmedizin Berlin | Prevention of impaired fracture healing |
EP4260907A1 (en) | 2022-04-11 | 2023-10-18 | Universität Zürich | Agents for treatment of endometriosis and other benign gynecological neoplasms |
WO2024002914A1 (en) | 2022-06-27 | 2024-01-04 | Charité-Universitätsmedizin Berlin | Prediction of, and composition to improve, tendon healing |
AU2023317655A1 (en) | 2022-08-01 | 2025-01-23 | Molecular Partners Ag | Charge modified designed repeat domains and their use |
WO2024038307A1 (en) | 2022-08-19 | 2024-02-22 | Novartis Ag | Dosing regimens for sars-cov-2 binding molecules |
WO2024133013A1 (en) | 2022-12-19 | 2024-06-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. | Means and methods to target endogenous condensates |
WO2024165671A1 (en) | 2023-02-08 | 2024-08-15 | Immunos Therapeutics Ag | FUSION PROTEINS OF ß2 MICROGLOBULIN, HLA HEAVY CHAIN POLYPEPTIDES, AND INHIBITOR OF CD47-SIRPA |
WO2024179981A1 (en) | 2023-02-27 | 2024-09-06 | Molecular Partners Ag | Darpins for use in reducing renal accumulation of drugs |
WO2025008519A1 (en) | 2023-07-05 | 2025-01-09 | Universität Bern | Il-1ra blockers for treatment and prevention of sepsis |
WO2025021293A1 (en) | 2023-07-25 | 2025-01-30 | Universität Zürich | Disruption of rbr1 expression in plant cells |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5094941A (en) * | 1987-12-31 | 1992-03-10 | Zymogenetics, Inc. | Monoclonal antibodies to PDGF |
EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
US5348867A (en) | 1991-11-15 | 1994-09-20 | George Georgiou | Expression of proteins on bacterial surface |
CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
DE69834032T2 (en) | 1997-04-23 | 2006-12-07 | Universität Zürich | METHOD OF DETECTING NUCLEIC ACID MOLECULES COPYING FOR (POLY) PEPTIDES THAT INTERACT WITH TARGET MOLECULES |
WO2000032823A1 (en) | 1998-12-02 | 2000-06-08 | Phylos, Inc. | Dna-protein fusions and uses thereof |
EP2149604A1 (en) * | 2000-09-08 | 2010-02-03 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
WO2003025019A1 (en) * | 2001-09-20 | 2003-03-27 | Alexion Pharmaceuticals, Inc. | Anti-pdgf antibodies and methods for producing engineered antibodies |
ES2388138T3 (en) * | 2003-08-27 | 2012-10-09 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
CA2585435A1 (en) * | 2004-11-12 | 2006-05-18 | Bayer Schering Pharma Aktiengesellschaft | Recombinant newcastle disease virus |
WO2006129828A2 (en) | 2005-05-31 | 2006-12-07 | Canon Kabushiki Kaisha | Target substance capturing molecule |
JP5042218B2 (en) | 2005-07-08 | 2012-10-03 | ユニバーシティ・オブ・チューリッヒ | Phage display using translocation simultaneously with translation of the fusion polypeptide |
EP2863222A1 (en) | 2006-03-06 | 2015-04-22 | Amunix Operating Inc. | Unstructured recombinant polymers and uses thereof |
ES2422007T3 (en) | 2007-06-21 | 2013-09-06 | Univ Muenchen Tech | Biological active proteins that have increased stability in vivo and / or in vitro |
ES2614284T3 (en) | 2007-11-30 | 2017-05-30 | Glaxo Group Limited | Antigen binding constructs |
WO2009100990A1 (en) * | 2008-02-13 | 2009-08-20 | Dsm Ip Assets B.V. | Process for the production of a peptide |
WO2009115919A2 (en) * | 2008-03-19 | 2009-09-24 | Institut Pasteur | Reagentless fluorescent biosensors comprising a designed ankyrin repeat protein module, rational design methods to create reagentless fluorescent biosensors and methods of their use |
ES2836948T3 (en) * | 2008-11-03 | 2021-06-28 | Molecular Partners Ag | Binding proteins that inhibit VEGF-A receptor interaction |
TW201120210A (en) * | 2009-11-05 | 2011-06-16 | Hoffmann La Roche | Glycosylated repeat-motif-molecule conjugates |
TWI510246B (en) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | Modified binding proteins inhibiting the vegf-a receptor interaction |
KR20140032356A (en) * | 2010-11-26 | 2014-03-14 | 몰리큘라 파트너스 아게 | Improved n-terminal capping modules for designed ankyrin repeat protein |
EA201391607A1 (en) * | 2011-04-29 | 2014-04-30 | Янссен Байотек, Инк. | BINDING IL4 / IL13 PROTEINS WITH REPEATERS AND THEIR APPLICATION |
-
2013
- 2013-06-27 CN CN201380034192.1A patent/CN104508129A/en active Pending
- 2013-06-27 EP EP13731809.3A patent/EP2867360B1/en active Active
- 2013-06-27 JP JP2015519089A patent/JP2015522576A/en active Pending
- 2013-06-27 BR BR112014032316A patent/BR112014032316A2/en not_active IP Right Cessation
- 2013-06-27 SG SG11201408196RA patent/SG11201408196RA/en unknown
- 2013-06-27 MX MX2014015825A patent/MX2014015825A/en unknown
- 2013-06-27 HK HK15109777.3A patent/HK1209156A1/en unknown
- 2013-06-27 CA CA2877584A patent/CA2877584A1/en not_active Abandoned
- 2013-06-27 WO PCT/EP2013/063488 patent/WO2014001442A1/en active Application Filing
- 2013-06-27 KR KR20157002327A patent/KR20150023957A/en not_active Withdrawn
- 2013-06-27 RU RU2014150224A patent/RU2014150224A/en not_active Application Discontinuation
- 2013-06-27 AU AU2013283296A patent/AU2013283296A1/en not_active Abandoned
- 2013-06-27 US US13/928,973 patent/US9163070B2/en active Active
-
2014
- 2014-12-03 ZA ZA2014/08872A patent/ZA201408872B/en unknown
- 2014-12-11 IN IN2522MUN2014 patent/IN2014MN02522A/en unknown
- 2014-12-24 IL IL236428A patent/IL236428A0/en unknown
-
2015
- 2015-09-08 US US14/847,403 patent/US20150368302A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2877584A1 (en) | 2014-01-03 |
US9163070B2 (en) | 2015-10-20 |
WO2014001442A1 (en) | 2014-01-03 |
MX2014015825A (en) | 2015-08-10 |
CN104508129A (en) | 2015-04-08 |
RU2014150224A (en) | 2016-08-20 |
IL236428A0 (en) | 2015-02-26 |
EP2867360B1 (en) | 2019-05-08 |
ZA201408872B (en) | 2016-05-25 |
KR20150023957A (en) | 2015-03-05 |
JP2015522576A (en) | 2015-08-06 |
AU2013283296A1 (en) | 2015-02-05 |
HK1209156A1 (en) | 2016-03-24 |
US20140005125A1 (en) | 2014-01-02 |
IN2014MN02522A (en) | 2015-07-17 |
US20150368302A1 (en) | 2015-12-24 |
EP2867360A1 (en) | 2015-05-06 |
BR112014032316A2 (en) | 2017-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL236428A0 (en) | Designed ankyrin repeat proteins binding to platelet- derived growth factor | |
IL240838A0 (en) | Anti-lag-3 binding proteins | |
SG10201607962RA (en) | Artificial nucleic acid molecules | |
IL235128A0 (en) | Nucleic acid sample preparation | |
ZA201504023B (en) | Bcma antigen binding proteins | |
AP2015008266A0 (en) | 1L-18 binding molecules | |
IL222323A0 (en) | Tnf - alpha binding proteins | |
EP2932375A4 (en) | Matching opportunity to context | |
ZA201404481B (en) | Il-1 binding proteins | |
ZA201500203B (en) | Transposition-mediated identification of specific binding or functional proteins | |
SG11201504249XA (en) | Methods to control protein heterogeneity | |
PL2914287T3 (en) | Binding members to il-1 beta | |
IL235134A0 (en) | Il-6 binding molecules | |
EP2911694A4 (en) | Anti-infective binding proteins that bind aip2 | |
PL2851083T3 (en) | Radiation-sterilization-resistant protein composition | |
EP2999710A4 (en) | Peptides binding to parallel-stranded g-quadruplexes | |
GB201418608D0 (en) | Peridinin-chlorophyll binding proteins | |
GB201200563D0 (en) | Binding molecule | |
SG11201503862XA (en) | Biotinylated protein | |
GB201213672D0 (en) | Protein | |
GB201211286D0 (en) | Novel biological factor | |
GB201215901D0 (en) | Protein modification | |
GB201214293D0 (en) | Binding surfaces | |
GB201202569D0 (en) | Compositions for binding to amyloid proteins | |
GB201214501D0 (en) | Protein bites |